ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth
Open accessThe DOI matches its Crossref record.
Abstract
Activin receptor–like kinase-1 (ALK1) is a type I, endothelial cell–specific member of the transforming growth factor-β superfamily of receptors known to play an essential role in modulating angiogenesis and vessel maintenance. In the present study, we sought to examine the angiogenic and tumorigenic effects mediated upon the inhibition of ALK1 signaling using a soluble chimeric protein (ALK1-Fc). Of 29 transforming growth factor-β–related ligands screened by surface plasmon resonance, only bone morphogenetic protein (BMP9) and BMP10 displayed high-affinity binding to ALK1-Fc. In cell-based assays, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate. In a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor–, fibroblast growth factor–, and BMP10-mediated vessel formation. The growth of B16 melanoma explants was also inhibited significantly by ALK1-Fc in this assay. Finally, ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells. These data show the efficacy of chimeric ALK1-Fc proteins in mitigating vessel formation and support the view that ALK1-Fc is a powerful antiangiogenic agent capable of blocking vascularization. Mol Cancer Ther; 9(2); 379–
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
Bone Morphogenetic Protein (BMP) signaling in development and human diseases
Wang, R. N., Green, J., Wang, Z., Deng, Y., Qiao, M., Peabody, M., Zhang, Q., Ye, J., Yan, Z., Denduluri, S., et al. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.005 · Cited by 1,031
Signaling by members of the TGF-β family in vascular morphogenesis and disease
Pardali, E., Goumans, M.-J., & ten Dijke, P. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.006 · Cited by 401
ALK1 Signaling Inhibits Angiogenesis by Cooperating with the Notch Pathway
Larrivée, B., Prahst, C., Gordon, E., del Toro, R., Mathivet, T., Duarte, A., Simons, M., & Eichmann, A. (2012) · Developmental Cell · doi:10.1016/j.devcel.2012.02.005 · Cited by 359
“…blockade on angiogenesis was VEGF dependent, cautioning against the use of ALK1 inhibitors to treat pathological tumor angiogenesis (Hu-Lowe et al., 2011; Mitchell et al., 2010) because it indicates that ALK1 inhibition may lead to appearance of vascular lesions in regions of active angiogenesis.”
BackgroundBMP signaling in vascular diseases
Cai, J., Pardali, E., Sánchez-Duffhues, G., & ten Dijke, P. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.030 · Cited by 269
Metadata
- Authors
- Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J., & Kumar, R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2010-02-01
- Volume
- 9
- Issue
- 2
- Pages
- 379-388
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2104603588
- Cited by
- 155
- References
- 0
- FWCI
- 5.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-0650
- The paper
- Mitchell, D., Pobre, E. G., Mulivor, A. W., Grinberg, A. V., Castonguay, R., Monnell, T. E., Solban, N., Ucran, J. A., Pearsall, R. S., Underwood, K. W., Seehra, J., & Kumar, R. (2010). ALK1-Fc Inhibits Multiple Mediators of Angiogenesis and Suppresses Tumor Growth. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-0650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.